Literature DB >> 24583158

Oseltamivir-zanamivir combination therapy is not superior to zanamivir monotherapy in mice infected with influenza A(H3N2) and A(H1N1)pdm09 viruses.

Andrés Pizzorno1, Yacine Abed1, Chantal Rhéaume1, Guy Boivin2.   

Abstract

The efficacy of oseltamivir-zanamivir combination therapy compared to that of monotherapy was evaluated in mice infected with influenza A(H3N2) or A(H1N1)pdm09 viruses. For A(H3N2) virus, zanamivir monotherapy and oseltamivir-zanamivir combination showed significant reduction of mean weight loss compared to oseltamivir. Zanamivir monotherapy also conferred decreased mortality, weight loss and lung viral titers (LVT) compared to oseltamivir for A(H1N1)pdm09 wild-type virus. Intermediate benefits were observed for the oseltamivir-zanamivir combination. For the oseltamivir-resistant A(H1N1)pdm09 H275Y virus, the efficacy of oseltamivir-zanamivir was comparable to that of zanamivir and significantly higher than that of oseltamivir in terms of survival, weight loss and LVT.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Combination; Influenza; Neuraminidase inhibitors; Oseltamivir; Resistance; Zanamivir

Mesh：

Substances：

Year:  2014        PMID： 24583158     DOI： 10.1016/j.antiviral.2014.02.017

Source DB:  PubMed          Journal:  Antiviral Res        ISSN： 0166-3542            Impact factor:   5.970


  9 in total

1.  Reduction of Neuraminidase Activity Exacerbates Disease in 2009 Pandemic Influenza Virus-Infected Mice.

Authors:  Charlene Ranadheera; Mable W Hagan; Anders Leung; Brad Collignon; Todd Cutts; Steven Theriault; Carissa Embury-Hyatt; Darwyn Kobasa
Journal:  J Virol       Date:  2016-10-14       Impact factor: 5.103

2.  Heterosubtypic protection conferred by the human monoclonal antibody PN-SIA28 against influenza A virus lethal infections in mice.

Authors:  Miguel Retamal; Yacine Abed; Chantal Rhéaume; Francesca Cappelletti; Nicola Clementi; Nicasio Mancini; Massimo Clementi; Roberto Burioni; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2015-02-17       Impact factor: 5.191

3.  Oseltamivir-zanamivir combination therapy suppresses drug-resistant H1N1 influenza A viruses in the hollow fiber infection model (HFIM) system.

Authors:  Camilly P Pires de Mello; George L Drusano; Jonathan R Adams; Matthew Shudt; Robert Kulawy; Ashley N Brown
Journal:  Eur J Pharm Sci       Date:  2017-10-25       Impact factor: 4.384

4.  Efficacy of oseltamivir-peramivir combination therapy compared to oseltamivir monotherapy for Influenza A (H7N9) infection: a retrospective study.

Authors:  Yan Zhang; Hainv Gao; Weifeng Liang; Lingling Tang; Yida Yang; Xiaoxin Wu; Liang Yu; Ping Chen; Shufa Zheng; Huilin Ou; Lanjuan Li
Journal:  BMC Infect Dis       Date:  2016-02-10       Impact factor: 3.090

Review 5.  Drug Repurposing Approaches for the Treatment of Influenza Viral Infection: Reviving Old Drugs to Fight Against a Long-Lived Enemy.

Authors:  Andrés Pizzorno; Blandine Padey; Olivier Terrier; Manuel Rosa-Calatrava
Journal:  Front Immunol       Date:  2019-03-19       Impact factor: 7.561

Review 6.  Influenza and antiviral resistance: an overview.

Authors:  Temi Lampejo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-02-13       Impact factor: 3.267

7.  Pharmacokinetic and pharmacodynamic analysis of baloxavir marboxil, a novel cap-dependent endonuclease inhibitor, in a murine model of influenza virus infection.

Authors:  Yoshinori Ando; Takeshi Noshi; Kenji Sato; Toru Ishibashi; Yuki Yoshida; Takahiro Hasegawa; Motoyasu Onishi; Mitsutaka Kitano; Ryoko Oka; Makoto Kawai; Ryu Yoshida; Akihiko Sato; Takao Shishido; Akira Naito
Journal:  J Antimicrob Chemother       Date:  2021-01-01       Impact factor: 5.790

Review 8.  Influenza antivirals and animal models.

Authors:  C Joaquin Caceres; Brittany Seibert; Flavio Cargnin Faccin; Stivalis Cardenas-Garcia; Daniela S Rajao; Daniel R Perez
Journal:  FEBS Open Bio       Date:  2022-04-27       Impact factor: 2.792

9.  In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses.

Authors:  Liva Checkmahomed; Blandine Padey; Andrés Pizzorno; Olivier Terrier; Manuel Rosa-Calatrava; Yacine Abed; Mariana Baz; Guy Boivin
Journal:  Viruses       Date:  2020-10-08       Impact factor: 5.048
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.